Efficacy of Natalizumab in Intermediate Uveitis Related to Multiple Sclerosis: A Case Report

Klin Monbl Augenheilkd 2018; 235(04): 476-477
DOI: 10.1055/s-0043-124756

Der interessante Fall

Georg Thieme Verlag KG Stuttgart · New York

Wirksamkeit von Natalizumab bei intermediärer Uveitis bei Multipler Sklerose: ein Fallbericht

Ségolène Roemer

¹Department of Ophthalmology, Jules Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland

,

Alexandre Bissig

¹Department of Ophthalmology, Jules Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland

,

Alda Rocca

²Department of Clinical Neurosciences, Neurosurgery Unit, University Hospital CHUV, Lausanne, Switzerland

,

Renaud Du Pasquier

³Laboratory of Neuroimmunology, Service of Neurology, Department of Clinical Neurosciences, University of Lausanne, CHUV, Lausanne, Switzerland

,

Yan Guex-Crosier

¹Department of Ophthalmology, Jules Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland

References
1 Alghatani H, Shirah B, Alassiri A. Tumefactive demyelinating lesions: a comprehensive review. Mult Scler Relat Disord 2017; 14: 72-79
2 Ghosh S, Goldin E, Gordon FH. et al. Natalizumab for active Crohnʼs disease. N Engl J Med 2003; 348: 24-32
3 Brandstadter R, Katz Sand I. The use of natalizumab for multiple sclerosis. Neuropsychiatr Dis Treat 2017; 13: 1691-1702
4 Olsen TG, Frederiksen J. The association between multiple sclerosis and uveitis. Surv Ophthalmol 2017; 62: 89-95
5 Dwivedi RA, Dwivedi RE, Durnian JM. et al. Tumefactive demyelination: an unusual cause of a spontaneously resolving homonymous hemianopia. BMJ Case Rep 2013;
6 Nakamura M, Itani K, Miyake K. et al. Natalizumab is effective for the treatment of relapsing-remitting tumefactive multiple sclerosis. Intern Med 2017; 56: 211-214
7 Jouve L, Benrabah R, Heron E. et al. Multiple sclerosis-related uveitis: does MS treatment affect uveitis course?. Ocul Immunol Inflam 2017; 25: 302-307